{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "OPTI.L",
  "generated_at": "2026-01-17T11:51:34.643709Z",
  "top_card": {
    "ticker": "OPTI.L",
    "company_name": "OptiBiotix Health Plc",
    "sector": "Healthcare",
    "market_cap_gbp": 6559569,
    "days_active": 932,
    "apex_score_100": 60,
    "confidence_score_100": 40,
    "ai_final_score_25": 12,
    "ai_strength": "MODERATE",
    "timing_regime": "TOO_EARLY",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - TOO_EARLY timing with 60/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "OptiBiotix Health Plc",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 6559569,
      "current_close_price": 6.35
    },
    "basics": {
      "ticker": "OPTI.L",
      "current_price": 6.35,
      "ath": 72.7,
      "atl": 5.57,
      "ath_date": "2020-02-04",
      "atl_date": "2023-06-29",
      "week_52_high": 21.0,
      "week_52_low": 5.634,
      "week_52_high_date": "2025-05-06",
      "week_52_low_date": "2026-01-06",
      "drawdown_from_ath_pct": 91.27,
      "data_start": "2020-01-02",
      "data_end": "2026-01-16",
      "total_bars": 1526
    },
    "latest_signal": {
      "date": "2023-06-29",
      "scan_date": "2026-01-14",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 6.4,
      "drawdown_pct": 84.0,
      "ai_score": 10.0,
      "rsi": 20.5,
      "cycle_position": 0.1618,
      "holding_period_days": 932,
      "current_pnl_pct": -0.78,
      "rally_state": "accumulating",
      "distance_from_high_pct": -83.93,
      "Rally_Count": 1,
      "days_since_last_high": 12,
      "last_high_date": "2026-01-02",
      "lock_in_reached": true,
      "lock_in_date": "2023-08-04",
      "best_rally_pct": 509.38
    },
    "best_historical_signal": {
      "signal_date": "2023-06-28",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "entry_price": 6.0,
      "peak_price": 43.495,
      "peak_date": "2023-07-26",
      "rally_pct": 624.92,
      "days_to_peak": 28,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "OPTI.L_2023-06-09",
        "signal_date": "2023-06-09",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.55,
        "current_price": 6.2665,
        "current_return_pct": -17.0,
        "best_rally_pct": 416.56,
        "best_rally_date": "2023-08-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -83.93,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 950,
        "status": "historical"
      },
      {
        "signal_id": "OPTI.L_2023-06-27",
        "signal_date": "2023-06-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 6.75,
        "current_price": 6.2665,
        "current_return_pct": -7.16,
        "best_rally_pct": 477.78,
        "best_rally_date": "2023-08-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -83.93,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 932,
        "status": "historical"
      },
      {
        "signal_id": "OPTI.L_2023-06-28",
        "signal_date": "2023-06-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.0,
        "current_price": 6.2665,
        "current_return_pct": 4.44,
        "best_rally_pct": 550.0,
        "best_rally_date": "2023-08-04",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -83.93,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 931,
        "status": "historical"
      },
      {
        "signal_id": "OPTI.L_2023-06-29",
        "signal_date": "2023-06-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 6.4,
        "current_price": 6.2665,
        "current_return_pct": -2.09,
        "best_rally_pct": 509.38,
        "best_rally_date": "2023-08-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -83.93,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 930,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 4,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 556.25,
      "median_rally_pct": 561.99,
      "best_rally_pct": 624.92,
      "worst_rally_pct": 476.09
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN"
    ],
    "last_updated": "2026-01-17 01:26:46 UTC",
    "volatility": {
      "atr_normalized": 7.95,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "ACCUMULATION"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 60/100 indicates strong opportunity quality",
      "Timing regime: TOO_EARLY",
      "Historical profile: 1 rallies, 509% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "OPTI.L",
      "latest": [
        {
          "title": "Holding(s) in Company",
          "announcement_date": "8th Mar 2024",
          "release_time": "4:09 pm",
          "source": "RNS",
          "content": "8 Mar 2024 16:09\nRNS Number : 2231G\nOptiBiotix Health PLC\n08 March 2024\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nOptibiotix Health plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nFinance Yorkshire Seedcorn Fund (FYSCF)\nCity and country of registered office (if applicable)\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n01/03/2024\n6.\nDate on which issuer notified (DD/MM/YYYY):\n06/03/2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n6.27%\n6.27%\n5,713,314\nPosition of previous notification (if\napplicable)\n7.77%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BP0RTP38\n5,713,314\n6.27%\nSUBTOTAL 8. A\n5,713,314\n6.27%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nUK\nDate of completion\n06/03/2024\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUPUMUWUPCGQR"
        },
        {
          "title": "Directorate Change",
          "announcement_date": "8th Jan 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "8 Jan 2025 07:00\nRNS Number : 4568S\nOptiBiotix Health PLC\n08 January 2025\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\nDirectorate change\nOptiB\ni\not\ni\nx\nH\nealth\np\nl\nc (A\nI\nM\n: O\nP\nTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare\n,\na\nnn\no\nun\nces that, further to the announcement on 23 October 2024, David Blain has been appointed to the Board as Finance Director and Company Secretary effective from 7 January 2025\n.\nDavid is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.\nDavid's appointment to this part-time role will see him work closely with the OptiBiotix team to support the\nfocus on driving each business unit and the Group to profitability.\nPursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of David Jonathan Blain (aged 63):\nCurrent Directorships\nPrevious Directorships held in the past five years\nBlain Associates Limited\nApplied Graphene Materials Limited (formerly Applied Graphene Materials plc)\nApplied Graphene Materials LLC\nApplied Graphene Ventures Limited\nUniversal Matter GBR Ltd (formerly Applied Graphene Materials UK Limited)\nDavid Blain does not hold any ordinary shares, options or warrants over new ordinary shares in the Company.\nThere is no further information regarding David Blain required to be disclosed under the AIM Rules.\nStephen O'Hara, CEO of OptiBiotix commented:\n\"\nWe are pleased to confirm the\nappointment of David as Finance Director and Company Secretary. The appointment reflects the Board's focus on managing costs and building revenues to create profitable business units and an international business with well-known global brands.\"\nThe Directors of the Company are responsible for the release of this announcement.\nFor further information, please contact:\nOptiBiotix Health plc\nwww.optibiotix.com\nNeil Davidson, Chairman\nContact via Walbrook below\nStephen O'Hara, Chief Executive\nCairn Financial Advisers LLP (NOMAD)\nTel: 020 7213 0880\nLiam Murray / Jo Turner / Ludovico Lazzaretti\nPeterhouse Capital Limited (Joint Broker)\nTel: 020 7220 9797\nDuncan Vasey / Lucy Williams\nWalbrook PR Ltd\nMob: 07876 741 001\nAnna Dunphy\nAbout OptiBiotix\n-\nwww.optibiotix.com\nOptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.\nOptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.\nOptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBOAZDLFBEFLEBBK"
        },
        {
          "title": "Result of AGM",
          "announcement_date": "8th Aug 2024",
          "release_time": "12:29 pm",
          "source": "RNS",
          "content": "8 Aug 2024 12:29\nRNS Number : 7693Z\nOptiBiotix Health PLC\n08 August 2024\n8 August 2024\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\" or the \"Group\")\nResult of AGM\nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care\na\nnn\no\nun\nces that at the AGM held earlier today, all resolutions were duly passed.\nThe full voting results will be available on the website in due course here:\nhttps://www.optibiotix-ir.com/content/investors/\nFor further information, please contact:\nOptiBiotix Health plc\nwww.optibiotix.com\nNeil Davidson, Chairman\nContact via Walbrook below\nStephen O'Hara, Chief Executive\nCairn Financial Advisers LLP (NOMAD)\nTel: 020 7213 0880\nLiam Murray / Jo Turner / Ludovico Lazzaretti\nPeterhouse Capital Limited (Broker)\nTel: 020 7220 9797\nDuncan Vasey / Lucy Williams\nWalbrook PR Ltd\nMob: 07876 741 001\nAnna Dunphy\nAbout OptiBiotix\n-\nwww.optibiotix.com\nOptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.\nOptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.\nOptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGPPMBTMTTMBPI"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "8th Aug 2024",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "8 Aug 2024 07:00\nRNS Number : 6182Z\nSkinBioTherapeutics PLC\n08 August 2024\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nSKINBIOTHERAPEUTICS PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nOptibiotix Health Plc\nCity and country of registered office (if applicable)\nUK\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n07/08/2024\n6.\nDate on which issuer notified (DD/MM/YYYY):\n07/08/2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n11.03%\n11.03%\n24,940,639\nPosition of previous notification (if\napplicable)\n12.94%\n12.94%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BF33H870\n24,940,639\n11.03%\nSUBTOTAL 8. A\n24,940,639\n11.03%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nLondon\nDate of completion\n07/08/2024\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLPRMFTMTTMBJI"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "7th Apr 2025",
          "release_time": "5:34 pm",
          "source": "RNS",
          "content": "7 Apr 2025 17:34\nRNS Number : 9972D\nSkinBioTherapeutics PLC\n07 April 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BF33H870\nIssuer Name\nSKINBIOTHERAPEUTICS PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nOptibiotix Health plc\nCity of registered office (if applicable)\nYork\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n31-Mar-2025\n6. Date on which Issuer notified\n07-Apr-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n8.460000\n0.000000\n8.460000\n19600000\nPosition of previous notification (if applicable)\n9.580000\n0.000000\n9.580000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nOrdinary\n19600000\n8.460000\nSub Total 8.A\n19600000\n8.460000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n07-Apr-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLIRMFTMTJMBTA"
        }
      ],
      "themes": [
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 125,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "ACCUMULATION"
    },
    "volatility": {
      "atr_normalized": 7.95,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2023-08-04"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "INDUSTRIALS",
      "name": "Industrials",
      "icon": "\ud83c\udfed",
      "color": "#64748b",
      "crash_patterns": [
        "Order book decline or cancellations",
        "Margin compression (input costs)",
        "Cyclical demand weakness",
        "Project delays or overruns",
        "Working capital strain"
      ],
      "recovery_paths": [
        "Order book growth or new contracts",
        "Margin recovery (efficiency gains)",
        "Cyclical upturn (capex recovery)",
        "M&A consolidation",
        "Product innovation or new markets"
      ],
      "active_patterns": [
        "Project delays or overruns"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Order book value (forward revenue)",
        "Book-to-bill ratio",
        "Operating margin trends",
        "Working capital efficiency",
        "Capex cycles (customer industries)"
      ]
    },
    "panic_analysis": {
      "panic_score": 74,
      "signal": "HIGH_PANIC",
      "interpretation": "\ud83d\udfe0 Fear dominant - watch for reversal signs",
      "breakdown": {
        "price_destruction": 40,
        "volume_death": 18,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": true,
      "opportunity_reason": "\u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 40/40 points",
        "\ud83d\udcc9 Volume death: 18/20 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 509% proven capacity"
      ],
      "verdict": "\ud83c\udfaf CONTRARIAN OPPORTUNITY - Fear dominates but facts support recovery potential"
    },
    "crashhunter_signals": [
      {
        "type": "HIGH_PANIC",
        "icon": "\ud83d\udfe0",
        "text": "Fear 74/100",
        "color": "#f59e0b"
      },
      {
        "type": "EARLY",
        "icon": "\u23f0",
        "text": "Too Early",
        "color": "#3b82f6"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 60",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Directorate Change",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Result of AGM",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "BUY",
      "reason": "\ud83c\udfaf CrashHunter Signal: \u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "74/100",
          "pass": true,
          "icon": "\ud83d\udd34"
        },
        {
          "criterion": "Timing Regime",
          "value": "TOO_EARLY",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "60/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "1 active",
          "pass": true,
          "icon": "\ud83c\udfed"
        }
      ],
      "pass_rate": "5/5"
    },
    "contrarian_panic": {
      "total_score": 54,
      "band": "\ud83d\udfe1 MODERATE COMPRESSION (Top 30% - GOOD SETUP)",
      "components": {
        "compression": {
          "score": 26,
          "max": 40,
          "signals_30d": 4,
          "signals_60d": 4,
          "signals_90d": 4,
          "signals_per_week": 1.4,
          "total_signals": 4,
          "rsi_extreme_count": 3,
          "rsi_ultra_count": 2,
          "escalation_count": 1,
          "density_score": 12,
          "rsi_score": 7,
          "escalation_score": 4,
          "description": "1.4 signals/week | 3 RSI<20 | 1 escalations | \u26a1 HIGH COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "DEEP CRASH BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 8,
          "max": 15,
          "relative_volume": 7.07,
          "description": "High volume - Panic spike or interest"
        },
        "pop_potential": {
          "score": 15,
          "max": 15,
          "best_historical_rally": 550.0,
          "avg_rally": 488.4,
          "signal_count": 4,
          "description": "BIG POPPER - Historical 5x+ (550%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation"
        }
      },
      "ticker": "OPTI.L",
      "signal_date": "2023-06-29",
      "total_signals_history": 4
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +12 (AI_Technical_Score=10.0/20)",
      "Drawdown reversion potential: +17 (Drawdown_Pct=84.0%)",
      "Volume confirmation: +10 (Relative_Volume=7.1)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +16 (best_rally_pct=509%)"
    ],
    "technical_score": {
      "points": 12,
      "ai_score": 10.0,
      "reason": "AI Technical Score 10.0/20 translates to 12/25 points"
    },
    "drawdown_score": {
      "points": 17,
      "drawdown_pct": 84.0,
      "reason": "Drawdown of 84.0% gives 17/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 7.07,
      "reason": "Relative volume 7.07x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 16,
      "best_rally_pct": 509.38,
      "reason": "Best rally of 509% gives 16/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Historically strong runner - massive upside when it moves",
        "tag": "HIGH",
        "evidence": [
          "best_rally_pct=509%",
          "Rally_Count=1.0"
        ]
      },
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=TOO_EARLY",
          "current_return_pct=-2.1%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2023-06-29"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "TOO_EARLY",
    "run_multiple": -0.0,
    "current_run_pct": -2.09,
    "avg_historical_run_pct": 509.38
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows TOO_EARLY timing with 60/100 APEX score. Historical data shows 1 rallies averaging 509% upside. Current position: -2.1%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Strong historical rally behavior (509% best run)",
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "TOO_EARLY means you can get chopped before real move"
    ],
    "timing_translation": "It might be starting, but not proven yet. Wait for base + volume + catalysts.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}